Sachin Kamal-Bahl
Sachin Kamal-Bahl has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Justin Puckett
COVIA Health Solutions, Lansdale, PA
6 shared publications Jalpa A. Doshi
Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
5 shared publications- Scott F. Huntington
Yale University, New Haven, CT
5 shared publications Monika Raut
Merck & Co, Inc, Rahway, NJ
3 shared publicationsScott F. Huntington
Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
3 shared publicationsBruce Stuart
School of Pharmacy, University of Maryland , Baltimore, Maryland , USA
2 shared publications
Latest Publications
- Open Access
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting
Background/Objectives: Covalent Bruton’s tyrosine kinase inhibitors (cBTKis) and the BCL-2 inhibitor venetoclax (VEN) have largely replaced traditional chemotherapy in clinical guidelines for frontline treatment of chronic lymphocytic leukemia (CLL). However, real-world evidence comparing these therapies on key outcomes remains limited. This study examined overall survival (OS) and time to next treatment (TTNT) among U.S. Medicare beneficiaries initiating frontline CLL therapy. Methods: In this retrospective study using 2016–2023 national 100% Medicare fee-for-service claims, we identified 10,949 patients aged ≥65 who initiated CLL treatment between June 2019 and December 2022. Patients received VEN-based regimens (n = 1503), cBTKi-based regimens (n = 5956), or other regimens (n = 3490). Results: Kaplan-Meier analyses showed superior OS for VEN-based regimens compared with cBTKi-based regimens and other regimens; three-year survival was 77% for VEN, 67% for cBTKis, and 62% for other regimens. In Cox regression models, cBTKis (hazard ratio [HR] 1.48, 95% CI 1.31–1.67) and other therapies (HR 1.66, 95% CI 1.47–1.89) were associated with worse OS relative to VEN. TTNT results also favored VEN; the percentage of patients with no evidence of second-line treatment at 3-years higher for VEN-based regimens (86%) compared to cBTKi-based regimens (69%) and other regimens (52%), despite similar follow-up times (median [months] VEN = 26.6, cBTKis = 26.2, Other = 21.8). cBTKis (HR 2.69, 95% CI 2.23–3.26) and other regimens (HR 6.47, 95% CI 5.32–7.86) were associated with a greater hazard for subsequent treatment relative to VEN. Conclusions: Our study demonstrates better survival and reduced need for subsequent treatment with VEN in patients with CLL treated in the frontline setting.
Open AccessReal-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting
Background/Objectives: Covalent Bruton’s tyrosine kinase inhibitors (cBTKis) and the BCL-2 inhibitor venetoclax (VEN) have largely replaced traditional chemotherapy in clinical guidelines for frontline treatment of chronic lymphocytic leukemia (CLL). However, real-world evidence comparing these therapies on key outcomes remains limited. This study examined overall survival (OS) and time to next treatment (TTNT) among U.S. Medicare beneficiaries initiating frontline CLL therapy. Methods: In this retrospective study using 2016–2023 national 100% Medicare fee-for-service claims, we identified 10,949 patients aged ≥65 who initiated CLL treatment between June 2019 and December 2022. Patients received VEN-based regimens (n = 1503), cBTKi-based regimens (n = 5956), or other regimens (n = 3490). Results: Kaplan-Meier analyses showed superior OS for VEN-based regimens compared with cBTKi-based regimens and other regimens; three-year survival was 77% for VEN, 67% for cBTKis, and 62% for other regimens. In Cox regression models, cBTKis (hazard ratio [HR] 1.48, 95% CI 1.31–1.67) and other therapies (HR 1.66, 95% CI 1.47–1.89) were associated with worse OS relative to VEN. TTNT results also favored VEN; the percentage of patients with no evidence of second-line treatment at 3-years higher for VEN-based regimens (86%) compared to cBTKi-based regimens (69%) and other regimens (52%), despite similar follow-up times (median [months] VEN = 26.6, cBTKis = 26.2, Other = 21.8). cBTKis (HR 2.69, 95% CI 2.23–3.26) and other regimens (HR 6.47, 95% CI 5.32–7.86) were associated with a greater hazard for subsequent treatment relative to VEN. Conclusions: Our study demonstrates better survival and reduced need for subsequent treatment with VEN in patients with CLL treated in the frontline setting.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 16, 567-579
Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia
Purpose: Little is known about adherence to and discontinuation of newly initiated oral antipsychotics (OAPs) as well as associated factors among Medicare beneficiaries with schizophrenia. This study aimed to examine rates of OAP adherence and discontinuation and associated factors in a national sample of fee-for-service Medicare beneficiaries with schizophrenia. Patients and Methods: This retrospective study used 100% fee-for-service Medicare claims data to identify adult beneficiaries with schizophrenia, initiating a new OAP between 01/01/2017 and 12/31/2019 (index date = date of new OAP prescription). Outcomes included adherence and discontinuation. Factors associated with adherence were assessed using logistic and linear regressions; Cox regressions were used to assess factors associated with discontinuation. Results: In our final sample of 46,452 Medicare beneficiaries with schizophrenia, 35.4% were adherent to their newly initiated OAP (mean [SD] PDC: 0.52 [0.37]) over 12 months after initiation. Most patients (79.4%) discontinued their new OAP (median [IQR] time to discontinuation: 3.6 (1.0, 9.9) months). Factors associated with lower odds of adherence included younger age (OR: 0.43; 95% CI: 0.40– 0.47, p < 0.001 for patients aged 18– 35 relative to patients aged ≥ 65 years); non-White race (OR: 0.72; 95% CI: 0.69– 0.75, p < 0.001 relative to White patients); and evidence of prior schizophrenia-related hospitalization (OR: 0.80; 95% CI: 0.77– 0.83, p < 0.001 relative to patients without evidence of prior schizophrenia-related hospitalization). Similar associations were observed for discontinuation outcomes. Twice-daily dosing frequency was also associated with lower odds of adherence (odds ratio [OR]: 0.93; 95% CI: 0.89– 0.97, p = 0.0014) and higher hazard of discontinuation (hazard ratio [HR]: 1.03; 95% CI: 1.00– 1.05, p = 0.0244) relative to once-daily dosing frequency. Conclusion: We found high rates of non-adherence and discontinuation among Medicare beneficiaries initiated on currently available OAPs. We also identified risk factors that contribute to increased odds of medication non-adherence. By identifying at-risk patient populations, targeted interventions can be initiated to facilitate treatment continuity.Plain Language Summary: Although half of patients with schizophrenia are covered by Medicare, little is known about how consistently they take their antipsychotic medications, which is a crucial part of successful treatment. We found that only 1/3 of Medicare beneficiaries consistently took their medications and nearly 80% discontinued treatment, often shortly after starting it. Younger patients, non-White patients, and patients who had to take pills multiple times per day were less likely to consistently take their medications.
- 1 August 2024
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 16, 567-579
Open AccessReal-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia
Purpose: Little is known about adherence to and discontinuation of newly initiated oral antipsychotics (OAPs) as well as associated factors among Medicare beneficiaries with schizophrenia. This study aimed to examine rates of OAP adherence and discontinuation and associated factors in a national sample of fee-for-service Medicare beneficiaries with schizophrenia. Patients and Methods: This retrospective study used 100% fee-for-service Medicare claims data to identify adult beneficiaries with schizophrenia, initiating a new OAP between 01/01/2017 and 12/31/2019 (index date = date of new OAP prescription). Outcomes included adherence and discontinuation. Factors associated with adherence were assessed using logistic and linear regressions; Cox regressions were used to assess factors associated with discontinuation. Results: In our final sample of 46,452 Medicare beneficiaries with schizophrenia, 35.4% were adherent to their newly initiated OAP (mean [SD] PDC: 0.52 [0.37]) over 12 months after initiation. Most patients (79.4%) discontinued their new OAP (median [IQR] time to discontinuation: 3.6 (1.0, 9.9) months). Factors associated with lower odds of adherence included younger age (OR: 0.43; 95% CI: 0.40– 0.47, p < 0.001 for patients aged 18– 35 relative to patients aged ≥ 65 years); non-White race (OR: 0.72; 95% CI: 0.69– 0.75, p < 0.001 relative to White patients); and evidence of prior schizophrenia-related hospitalization (OR: 0.80; 95% CI: 0.77– 0.83, p < 0.001 relative to patients without evidence of prior schizophrenia-related hospitalization). Similar associations were observed for discontinuation outcomes. Twice-daily dosing frequency was also associated with lower odds of adherence (odds ratio [OR]: 0.93; 95% CI: 0.89– 0.97, p = 0.0014) and higher hazard of discontinuation (hazard ratio [HR]: 1.03; 95% CI: 1.00– 1.05, p = 0.0244) relative to once-daily dosing frequency. Conclusion: We found high rates of non-adherence and discontinuation among Medicare beneficiaries initiated on currently available OAPs. We also identified risk factors that contribute to increased odds of medication non-adherence. By identifying at-risk patient populations, targeted interventions can be initiated to facilitate treatment continuity.Plain Language Summary: Although half of patients with schizophrenia are covered by Medicare, little is known about how consistently they take their antipsychotic medications, which is a crucial part of successful treatment. We found that only 1/3 of Medicare beneficiaries consistently took their medications and nearly 80% discontinued treatment, often shortly after starting it. Younger patients, non-White patients, and patients who had to take pills multiple times per day were less likely to consistently take their medications.
- 4 June 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (10) , e350-e358.e1
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
- 4 June 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (10) , e350-e358.e1
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
- Open Access
- 9 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (5) , e181-e190
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
- 9 February 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (5) , e181-e190
Open AccessReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
- Open Access
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6953
Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Background: The first‐generation BTK inhibitor ibrutinib is a standard‐of‐care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.Methods: This study used 2013–2019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.Results: The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow‐up of 2.3 years. The overall incidence rate of AEs was 62.5 per 1000 patient‐months for all discontinuers and 32.9 per 1000 patient‐months for non‐discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient‐months compared with non‐discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia/myalgia (19.5 vs. 13.6).Conclusion: In this first real‐world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib‐related AEs and/or new treatments to improve real‐world outcomes in patients with CLL.
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6953
Open AccessReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Background: The first‐generation BTK inhibitor ibrutinib is a standard‐of‐care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.Methods: This study used 2013–2019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.Results: The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow‐up of 2.3 years. The overall incidence rate of AEs was 62.5 per 1000 patient‐months for all discontinuers and 32.9 per 1000 patient‐months for non‐discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient‐months compared with non‐discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia/myalgia (19.5 vs. 13.6).Conclusion: In this first real‐world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib‐related AEs and/or new treatments to improve real‐world outcomes in patients with CLL.
- Open Access
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- 5 December 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (6) , 317-328
Open AccessReal-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare pat... Plain language summary – Older patients with DLBCL need more effective treatments Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common w... Tweetable abstract A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and sub...
- Open Access
- 21 September 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (14) , 2316-2323
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the availability of Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Despite clinical trial data supporting these novel oral agents, evidence evaluating real-world adherence is limited. This study used 2015-2019 Medicare claims data for elderly patients with relapsed/refractory CLL to assess differences in real-world adherence and discontinuation in the 12 months after treatment initiation. In the final sample of 711 venetoclax patients and 1,566 BTKi patients, we found that those initiating venetoclax tended to be younger (mean age 75.6 [SD 6.0] vs 77.6 [SD 6.9] years, p < .001) but had poorer clinical characteristics. After risk-adjustment, the venetoclax group had higher adherence (61.9% vs. 45.4%, p < .0001) and lower discontinuation when compared to the BTKi group (28.5% vs. 47.4%, p < .001). These favorable real-world findings underscore the importance of developing well-tolerated novel combinations for older adults.
- 21 September 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (14) , 2316-2323
Open AccessReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the availability of Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Despite clinical trial data supporting these novel oral agents, evidence evaluating real-world adherence is limited. This study used 2015-2019 Medicare claims data for elderly patients with relapsed/refractory CLL to assess differences in real-world adherence and discontinuation in the 12 months after treatment initiation. In the final sample of 711 venetoclax patients and 1,566 BTKi patients, we found that those initiating venetoclax tended to be younger (mean age 75.6 [SD 6.0] vs 77.6 [SD 6.9] years, p < .001) but had poorer clinical characteristics. After risk-adjustment, the venetoclax group had higher adherence (61.9% vs. 45.4%, p < .0001) and lower discontinuation when compared to the BTKi group (28.5% vs. 47.4%, p < .001). These favorable real-world findings underscore the importance of developing well-tolerated novel combinations for older adults.
- Open Access
- 27 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (11) , 1752-1770
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Studies evaluating real-world outcomes and health care utilization for mantle cell lymphoma are limited. We utilized national Medicare claims (2009-2019) to examine treatment patterns, healthcare resource utilization, costs, and survival in 3664 elderly patients receiving 1 L treatment for MCL. Over a median follow-up of 2.8 years, 40.3% received at least 2 L treatment. The most common 1 L regimen was bendamustine-rituximab (50.1%), with increased use of BTKi-based regimens observed in 2 L (39.4%). Half (51.8%) of patients had an all-cause hospitalization within 12 months of initiating 1 L; hospitalization rates were higher in later lines. Healthcare costs were substantial and most costs (>80%) were MCL-related. Overall survival was poorer among later lines of treatment (median OS from initiation of 1 L: 53.5 months; 2 L: 22.0 months; 3 L: 11.8 months; 4 L: 7.8 months). These results suggest a large unmet need and future work should evaluate whether novel therapies have improved outcomes among elderly patients with MCL.
- 27 July 2023
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (11) , 1752-1770
Open AccessAssessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Studies evaluating real-world outcomes and health care utilization for mantle cell lymphoma are limited. We utilized national Medicare claims (2009-2019) to examine treatment patterns, healthcare resource utilization, costs, and survival in 3664 elderly patients receiving 1 L treatment for MCL. Over a median follow-up of 2.8 years, 40.3% received at least 2 L treatment. The most common 1 L regimen was bendamustine-rituximab (50.1%), with increased use of BTKi-based regimens observed in 2 L (39.4%). Half (51.8%) of patients had an all-cause hospitalization within 12 months of initiating 1 L; hospitalization rates were higher in later lines. Healthcare costs were substantial and most costs (>80%) were MCL-related. Overall survival was poorer among later lines of treatment (median OS from initiation of 1 L: 53.5 months; 2 L: 22.0 months; 3 L: 11.8 months; 4 L: 7.8 months). These results suggest a large unmet need and future work should evaluate whether novel therapies have improved outcomes among elderly patients with MCL.
- Open Access
- 2 September 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (10) , ofac435
Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
The 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) Clostridium (Clostridioides) difficile infection (CDI) guideline update recommended treatment with fidaxomicin or vancomycin for CDI. We aimed to examine outpatient CDI treatment utilization before and after the guideline update and compare clinical outcomes associated with fidaxomicin versus vancomycin use. A pre-post study design was employed using Medicare data. CDI treatment utilization and clinical outcomes (4- and 8-week sustained response, CDI recurrence) were compared between patients indexed from April–September 2017 (preguideline period) and those indexed from April–September 2018 (postguideline period). Clinical outcomes associated with fidaxomicin versus vancomycin were compared using propensity score–matched analyses. From the pre- to postguideline period, metronidazole use decreased (initial CDI: 81.2% to 53.5%; recurrent CDI: 49.7% to 27.6%) while vancomycin (initial CDI: 17.9% to 44.9%; recurrent CDI: 48.1% to 66.4%) and fidaxomicin (initial CDI: 0.87% to 1.63%; recurrent CDI: 2.2% to 6.0%) use increased significantly (P < .001 for all). However, clinical outcomes did not improve. In propensity score–matched analyses, fidaxomicin versus vancomycin users had 4-week sustained response rates that were higher by 13.5% (95% confidence interval [CI], 4.0%–22.9%; P = .0058) and 30.0% (95% CI, 16.8%–44.3%; P = .0002) in initial and recurrent CDI cohorts, respectively. Recurrence rates were numerically lower for fidaxomicin in both cohorts. Vancomycin use increased and metronidazole use decreased after the 2017 guideline update. Fidaxomicin use increased but remained low. Improved outcomes associated with fidaxomicin relative to vancomycin suggest benefits from its greater use in Medicare patients.
- 2 September 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (10) , ofac435
Open AccessImpact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
The 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) Clostridium (Clostridioides) difficile infection (CDI) guideline update recommended treatment with fidaxomicin or vancomycin for CDI. We aimed to examine outpatient CDI treatment utilization before and after the guideline update and compare clinical outcomes associated with fidaxomicin versus vancomycin use. A pre-post study design was employed using Medicare data. CDI treatment utilization and clinical outcomes (4- and 8-week sustained response, CDI recurrence) were compared between patients indexed from April–September 2017 (preguideline period) and those indexed from April–September 2018 (postguideline period). Clinical outcomes associated with fidaxomicin versus vancomycin were compared using propensity score–matched analyses. From the pre- to postguideline period, metronidazole use decreased (initial CDI: 81.2% to 53.5%; recurrent CDI: 49.7% to 27.6%) while vancomycin (initial CDI: 17.9% to 44.9%; recurrent CDI: 48.1% to 66.4%) and fidaxomicin (initial CDI: 0.87% to 1.63%; recurrent CDI: 2.2% to 6.0%) use increased significantly (P < .001 for all). However, clinical outcomes did not improve. In propensity score–matched analyses, fidaxomicin versus vancomycin users had 4-week sustained response rates that were higher by 13.5% (95% confidence interval [CI], 4.0%–22.9%; P = .0058) and 30.0% (95% CI, 16.8%–44.3%; P = .0002) in initial and recurrent CDI cohorts, respectively. Recurrence rates were numerically lower for fidaxomicin in both cohorts. Vancomycin use increased and metronidazole use decreased after the 2017 guideline update. Fidaxomicin use increased but remained low. Improved outcomes associated with fidaxomicin relative to vancomycin suggest benefits from its greater use in Medicare patients.
- 1 June 2022
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 28 (6) , 273-280
Financial incentives tied to Medicare star ratings: impact on influenza vaccination uptake in Medicare beneficiaries
Influenza vaccine uptake improved among Medicare Advantage enrollees when influenza vaccination was introduced as a performance metric in Medicare star ratings and accompanying bonus payments.
- 1 June 2022
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 28 (6) , 273-280
Financial incentives tied to Medicare star ratings: impact on influenza vaccination uptake in Medicare beneficiaries
Influenza vaccine uptake improved among Medicare Advantage enrollees when influenza vaccination was introduced as a performance metric in Medicare star ratings and accompanying bonus payments.